Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ellinghaus

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cardiovascular Research|June 17, 2011
A role for coagulation factor Xa in experimental pulmonary arterial hypertensionMartina Delbeck, Katrin F Nickel, Elisabeth Perzborn, et al.
Experimental and Clinical Cardiology|January 26, 2010
Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery diseaseReiner Füth, Wilfried Dinh, Werner Nickl, et al.
European Journal of Applied Physiology|November 22, 2017
New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventionsThomas Mondritzki, Philip Boehme, Lena Schramm, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 28, 2008
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devicesHendrik Milting, Peter Ellinghaus, Michael Seewald, et al.
Physiological Genomics|May 13, 2010
Global gene expression analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile ventricular assist device supportPatrick Schwientek, Peter Ellinghaus, Sonja Steppan, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Cancer Medicine|January 10, 2014
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex IPeter Ellinghaus, Iring Heisler, Kerstin Unterschemmann, et al.
Physiological Genomics|March 19, 2009
Genomic profiling of developing cardiomyocytes from recombinant murine embryonic stem cells reveals regulation of transcription factor clustersMichael J Seewald, Peter Ellinghaus, Astrid Kassner, et al.
Circulation|October 29, 2008
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodelingMartina Klein, Ralph T Schermuly, Peter Ellinghaus, et al.
International Journal of Cancer|February 27, 2019
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer modelsSylvia Grünewald, Oliver Politz, Sebastian Bender, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cardiovascular Research|June 17, 2011
A role for coagulation factor Xa in experimental pulmonary arterial hypertensionMartina Delbeck, Katrin F Nickel, Elisabeth Perzborn, et al.
Experimental and Clinical Cardiology|January 26, 2010
Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery diseaseReiner Füth, Wilfried Dinh, Werner Nickl, et al.
European Journal of Applied Physiology|November 22, 2017
New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventionsThomas Mondritzki, Philip Boehme, Lena Schramm, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 28, 2008
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devicesHendrik Milting, Peter Ellinghaus, Michael Seewald, et al.
Physiological Genomics|May 13, 2010
Global gene expression analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile ventricular assist device supportPatrick Schwientek, Peter Ellinghaus, Sonja Steppan, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Cancer Medicine|January 10, 2014
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex IPeter Ellinghaus, Iring Heisler, Kerstin Unterschemmann, et al.
Physiological Genomics|March 19, 2009
Genomic profiling of developing cardiomyocytes from recombinant murine embryonic stem cells reveals regulation of transcription factor clustersMichael J Seewald, Peter Ellinghaus, Astrid Kassner, et al.
Circulation|October 29, 2008
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodelingMartina Klein, Ralph T Schermuly, Peter Ellinghaus, et al.
International Journal of Cancer|February 27, 2019
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer modelsSylvia Grünewald, Oliver Politz, Sebastian Bender, et al.
Pageof 4